E-DRUG: Rejection of Sofosbuvir patent application in Inda: 6087/DELNP/2005
------------------------------------------------------------------------------------------------------------
The grant of patent to the application 6087/DELNP/2005 in India has been
rejected because of lack of information on efficacy.
In a Seminar held in Brazil on April 2014 it was discussed that, because
the low production cost ($2- 4 per g), a reasonable treatment cost could
be $103.7 to $204.85 US$ (12 weeks) - currently charged $84,000 to $168,000.
All this together gives floor to a very important discussion.
Vera Lucia Luiza
Vera Lucia Luiza MSc DSc
Coordinator
Nucleus of Pharmaceutical Policies (NAF);
National School of Public Health (ENSP)
NAF / ENSP / Fiocruz
Rua Leopoldo Bulh_es 1480/624, Manguinhos
21041 210 - Rio de Janeiro RJ
++55 21 2598-2762 and 2598-2591; Fax: 2209-3076, 4042-5801
Vera Lucia BR <negritudesenior@gmail.com>